Université´ D'aix-marseille

Assistance Publique Hopitaux De Marseille

Universidad De Oviedo

Université De La Méditerranée - Aix-marseille II

Association Francaise Contre Les Myopathies (afm)

Association Francaise Contre Les Myophathies (afm)

Centre National De La Recherche Scientifique-cnrs

Association Francaise Contre Les Myopathies

Inserm

Progelife

Pierre Cau

Nicolas Levy

Karim Harhouri

Carlos Lopez-Otin

Sophie Perrin

Martine Simonelig

Vincent Bonniol

Annachiara De Sandre-Giovannoli

Aymeric Chartier

Patrice Bourgeois

Nicolas Lévy

This invention relates to a composition comprising an anti-HIV treatment and a treatment for side effects of said anti-HIV treatment in an HIV-infected patient. This invention is, for example, very useful in the treatment of side effects caused by certain anti-HIV treatments, for example premature aging and lipodystrophy, which can be caused by protease inhibitors or reverse transcriptase inhibitors. The composition of this invention includes at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor, at least one farnesyl-pyrophosphate synthase inhibitor, and at least one anti-HIV agent. One of the processes for treating an HIV-infected patient includes, in any order, the following steps: (i) administration of a mixture including at least one hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and at least one farnesyl-pyrophosphate synthase inhibitor and (ii) administration of an anti-HIV agent, in which the administrations are concomitant, successive or alternative.

Composition and methods used during anti-HIV treatment

The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological ageing.

Combination of an HMG-CoA reductase inhibitor and a farnesyl-pyrophosphate synthase inhibitor for the treatment of diseases related to the persistence and/or accumulation of prenylated proteins

The invention relates to the use of a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor and of a farnesyl-pyrophosphate synthase inhibitor, or of one of their associated physiologically acceptable salts, in the preparation of a composition, particularly a pharmaceutical composition, for use in the treatment of human or animal, pathological or nonpathological situations related to the accumulation and/or the persistence of prenylated proteins in cells, such as during progeria (Hutchinson-Gilford syndrome), restrictive dermopathy or physiological aging.

HMG-CoA reductase and farnesyl-pyrophosphate synthase inhibitors for the treatment of conditions related to prenylated proteins in cells

Growing community of inventors

Puyricard, France

Pierre Cau